Some of these authors have used CD138 as a selective marker for separating immunophenotypically normal from neoplastic plasma cells, and a recent report of the European Myeloma Network has demonstrated that a combination of CD138, CD38 and CD45 antibodies allows the most reproducible detection of neoplastic plasma cells [22]. This evidence concerns the gene SDC1 and plasma cell myeloma.